Volume 15 - Issue 12 - December, 2003
Coronary Fistula from Left Main Stem to Main Pulmonary Artery
- Fri, 8/1/08 - 12:12pm
- 0 Comments
- 4281 reads
Congenital coronary arteriovenous fistula (CAF) is a rare anomaly. The incidence of congenital cardiac lesions is only 0.13%.1 Over 90% of these fistulas drain into the systemic venous side of the circulation.2 Drainage of the fistula into the pulmonary trunk has been reported in 17% of cases.2 To the best of our knowledge, a connection between the left main stem and main pulmonary artery has been reported in the literature only once, as a case in India in 1989.3
Case Report. A 51-year-old female with hypertension was admitted to the hospital with her first attack of acute myocard
Comparison of Stainless-Steel Stents Coated with Turbostratic Carbon and Uncoated Stents for Percutaneous Coronary Interventions
- Fri, 8/1/08 - 12:12pm
- 0 Comments
- 3821 reads
Implantation of stainless-steel stents has improved the results of percutaneous coronary revascularization.1,2 However, in various subsets of lesions, especially in the presence of complex lesion morphology, in-stent restenosis due to late neointimal hyperplasia occurs in up to 50% of cases3–5 requiring repeated coronary interventions including intravascular brachytherapy.6,7 Various passive stent coatings have been proposed to reduce thrombus formation and intimal hyperplasia following stent implantation.8–10 However, none of these stent coatings have proven to prevent in-stent restenosis
Peptide-Treated Stent Graft for the Treatment of Saphenous Vein Graft Lesions: First Clinical Results
- Fri, 8/1/08 - 12:12pm
- 0 Comments
- 2102 reads
Percutaneous interventions of degenerated saphenous vein grafts (SVGs) are associated with high rates of distal embolic events and in-stent restenosis.1 Recent experience with covered stents suggests that these types of devices may be a promising alternative to bare stents or repeat bypass surgery in the treatment of diseased saphenous vein grafts.2–4 A new, ePTFE stent graft (Figure 1) has been developed, which incorporates a synthetic, cell-adhesion peptide (P-15) surface treatment.5 Pre-clinical studies of this device in the porcine model have demonstrated a rapid and complete regeneratio
Catheter-Based Revascularization of the Hepatic Artery to Treat Coronary Steal from a Gastroepiploic Artery Bypass Graft
- Fri, 8/1/08 - 12:12pm
- 0 Comments
- 5043 reads
For patients treated with coronary bypass surgery, atherosclerotic peripheral arterial disease may compromise blood flow to more distally located arterial bypass grafts. In most instances, proximal subclavian artery stenosis limits flow to the left internal mammary artery (LIMA) graft, resulting in myocardial ischemia. Although percutaneous revascularization of the subclavian artery to relieve ischemia related to the LIMA graft has been described,1–3 catheter-based revascularization of other peripheral arteries to treat steal phenomena from additional arterial conduits is not well characteri
The Influence of Diabetes Mellitus on the Practice and Outcomes of Percutaneous Coronary Intervention in the Community: A Report
- Fri, 8/1/08 - 12:12pm
- 0 Comments
- 2982 reads
Diabetic patients with coronary artery disease (CAD) have poorer long-term prognosis with more revascularization procedures than non-diabetic patients regardless of the initial treatment strategy.1,2 The role of percutaneous versus surgical revascularization as the initial treatment strategy for diabetic patients remains controversial. The Bypass Angioplasty Revascularization Investigation (BARI) trial found that diabetic patients with Multivessel coronary artery disease randomized to an initial strategy of PCTA versus CABG surgery had significantly higher mortality rates (34.7% versus 19.1%)
Updated Risk Adjustment Mortality Model Using the Complete 1.1 Dataset from the American College of Cardiology National Cardiova
- Fri, 8/1/08 - 12:13pm
- 0 Comments
- 2128 reads
The use of risk adjustment methodology to account for patient differences in treatment outcomes is imperative to legitimately compare the results of institutions performing cardiovascular intervention. Mortality has been the most widely used indicator to evaluate the quality of cardiac treatment procedures. In prior publications, the initial experience of the American College of Cardiology National Cardiovascular Data Registry (ACC-NCDR) was described1 and a mortality risk model based on data collected in 100,253 percutaneous coronary interventions (PCI) using version 1.1 data standards of the
Successful Exclusion of Descending Thoracic Aortic Pseudoaneurysm by Endovascular Stent-Graft Placement
- Fri, 8/1/08 - 12:13pm
- 0 Comments
- 2522 reads
Thoracic aortic aneurysm continues to be a life-threatening problem because of associated comorbid conditions and high morbidity and mortality associated with conventional open repair.1 Despite the remarkable improvements in treatment as a result of technical advances and improved prosthetic grafts, the operative mortality remains high.2 In addition to morbidity related to thoracotomy and cardiopulmonary bypass, open surgical resections and repairs are associated with bleeding, paraplegia, strokes, renal insufficiency and potential need for prolonged ventilatory support in the postoperative pe
How Should Diuretic-Refractory, Volume-Overloaded Heart Failure Patients Be Managed?
- Fri, 8/1/08 - 12:13pm
- 0 Comments
- 5612 reads
Clinical problem. Heart failure patients are frequently hospitalized with decompensated heart failure,1 usually with volume overload. Treatment guidelines recommend diuretics to optimize volume status,2 and are most effective administered intravenously. However, the management of patients refractory to diuretic therapy is not addressed in the guidelines of the American Heart Association/American College of Cardiology,3 the European Society of Cardiology4 or the Heart Failure Society of America.5
One problem with defining a treatment strategy in these patients is the lack of a consisten
- « Previous
- | Page 1 of 2 |
- Next »
